MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - Nature reviews Drug discovery, 2013 - nature.com
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR-34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …
被引用次数：1554 相关文章

MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - Nature reviews. Drug …, 2013 - pubmed.ncbi.nlm.nih.gov
The first cancer-targeted microRNA (miRNA) drug-MRX34, a liposome-based miR-34 mimic-
entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in April …
[PDF] gene-quantification.org

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gene-quantification.org
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …
[PDF] gene-quantification.net

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gene-quantification.net
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …
[PDF] gmo-qpcr-analysis.info

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gmo-qpcr-analysis.info
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …

[引用][C] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, GAC Muller Fabbri - Nature Reviews Drug Discovery, 2013 - cir.nii.ac.jp
MicroRNAs and other non-coding RNAs as targets for anticancer drug development | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[PDF] gene-quantification.net

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gene-quantification.net
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …
[HTML] europepmc.org

[HTML][HTML] MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

H Ling, M Fabbri, GA Calin - Nature reviews. Drug Discovery, 2013 - europepmc.org
With the first cancer-targeted microRNA drug, MRX34, a liposome-based miR-34 mimic,
entering phase I clinical trial in patients with advanced hepatocellular carcinoma in April …
[PDF] gmo-qpcr-analysis.info

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gmo-qpcr-analysis.info
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …
[PDF] gmo-qpcr-analysis.com

[PDF][PDF] MicroRNAs and other non-coding RNAs as targets for anticancer drug development

H Ling, M Fabbri, GA Calin - NATURE REVIEWS| DRUG …, 2013 - gmo-qpcr-analysis.com
The first cancer-targeted microRNA (miRNA) drug—MRX34, a liposome-based miR‑34
mimic—entered Phase I clinical trials in patients with advanced hepatocellular carcinoma in …